Globe Life Inc

GL is in a Stage 2 advancing regime supported by a primary Momentum Breakout, underpinned by higher highs and higher lows above rising EMAs. While the medium-term bias remains bullish, the short-term is extended and overbought with price well above the 9/21 EMAs, warranting deferred entries on pullbacks into the confluence of rising EMAs and the prior resistance-turned-support zone around ~177–181.

• ↑Q1 net income rose 6% to $271M ($3.39 EPS) with double-digit operating income growth
• ↑Projected health premium revenue up 14–17% in 2026, driven by Medicare supplement demand
• ↓Lapse rates expected to stay elevated in 2026, pressuring policy retention and revenue